Why Is Merck Stock Surging?

Core Insights - Merck's stock surged by 41% over the past six months, primarily driven by increased profits and investor confidence rather than significant revenue growth [2][3] - Key factors contributing to the stock rise include Q3 earnings exceeding expectations, FDA approval of Keytruda's new formulation, and an upgrade from Wells Fargo [2] Financial Performance - Q3 2025 revenue reached $17.3 billion, reflecting a 4% increase, with non-GAAP EPS at $2.58 and guidance for 2025 raised [9] - The net margin increased by 8.6%, while the P/E multiple saw a substantial rise of 28% [3] Key Developments - The FDA approved KEYTRUDA+Padcev for MIBC, marking a first-in-class regimen that expands Keytruda's market potential [9] - Wells Fargo upgraded Merck to Overweight based on pipeline progress and growth confidence following Keytruda's developments [9] - The launch of subcutaneous KEYTRUDA QLEX in the EU is expected to enhance future revenues after loss of exclusivity [9] Historical Context - Despite recent gains, Merck's stock has shown vulnerability during past market downturns, including a 63% loss during the Global Financial Crisis and a 27% decline during the Covid pandemic [7]